Patentability, Biosimilars Top Life Sciences Issues for 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together.

January 13, 2012

For the life sciences industry, 2012 will be a year when a lot of things are likely to come together, industry attorneys and executives told Bloomberg BNA during telephone interviews and e-mail exchanges in December.

They indicated that it could be a year when clarity about what is patentable subject matter is achieved from at least one and perhaps two Supreme Court rulings and when personalized medicine, which cuts across federal agencies, the private sector, and a number of other life sciences issues, could definitely become the focus of the industry. And it could be a year when implementing the abbreviated biosimilars approval pathway will result in stronger collaborations among biotechnology, pharmaceutical, and generic drug companies.

Reproduced with permission from Life Sciences Law & Industry Report, 6 LSLR 47 (Jan. 13, 2012). Copyright 2012 by The Bureau of National Affairs, Inc. (800-372-1033) http://www.bna.com

Related Publications

July 2020
Hatch-Waxman Patent Litigation Strategies
Jeffrey Alan Hovden - LexisNexis
July 20, 2020
Deadlines or Guidelines?
Eric Magnuson, Eric Boettcher - Minnesota Lawyer
Summer 2020
The Brave New World of Virtual Notarization
Steven Orloff, Manleen Singh - The Robins Kaplan Spotlight, Vol. 5, No. 2
Summer 2020
What Could be the Harm? Minnesota's Harmless Error Statute
Matthew Frerichs, Ena Kovacevic - The Robins Kaplan Spotlight, Vol. 5, No. 2
Back to Top